Transition Therapeutics tanked on Feb. 1 after announcing largely positive results for its diabetes candidate due to investor worry that big pharma partner Eli Lilly & Co. may not choose to commercialize the program.
The biotech's stock took a major hit, dropping as much as 30% to trade below $1 per share. The stock...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?